Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension by Leuchte, Hanno H. et al.
ORIGINAL ARTICLE
Residual pulmonary vasodilative reserve predicts
outcome in idiopathic pulmonary hypertension
Hanno H Leuchte,1,2 Carlos Baezner,2 Rainer A Baumgartner,1,2 Olaf Muehling,2


















Received 19 January 2015
Revised 31 March 2015
Accepted 15 April 2015
To cite: Leuchte HH,
Baezner C, Baumgartner RA,
et al. Heart 2015;101:
972–976.
ABSTRACT
Objective Idiopathic pulmonary arterial hypertension
(IPAH) remains a devastating and incurable, albeit
treatable condition. Treatment response is not uniform
and parameters that help to anticipate a rather benign
or a malignant course of the disease are warranted.
Acute pulmonary vasoreactivity testing during right heart
catheterisation is recommended to identify a minority of
patients with IPAH with sustained response to calcium
channel blocker therapy. This study aimed to evaluate
the prognostic significance of a residual pulmonary
vasodilative reserve in patients with IPAH not meeting
current vasoresponder criteria.
Design Observational right heart catheter study in
66 (n=66) patients with IPAH not meeting current
vasoresponse criteria. Pulmonary vasodilative reserve
was assessed by inhalation of 5 mg iloprost-aerosol.
Results Sixty-six (n=66) of 72 (n=72) patients with
IPAH did not meet current definition criteria assessed
during vasodilator testing to assess pulmonary
vasodilatory reserve. In those, iloprost-aerosol caused a
reduction of mean pulmonary artery pressure
(Δ pulmonary artery pressure—11.4%; p<0.001) and
increased cardiac output (Δ cardiac output +16.7%;
p<0.001), resulting in a reduction of pulmonary vascular
resistance (Δ pulmonary vascular resistance—25%;
p<0.001). The magnitude of this response was
pronounced in surviving patients. A pulmonary vascular
resistance reduction of ≥30% turned out to predict
outcome in patients with IPAH.
Conclusions Residual pulmonary vasodilative reserve
during acute vasodilator testing is of prognostic
relevance in patients with IPAH not meeting current
definitions of acute vasoreactivity. Therefore
vasoreactivity testing holds more information than
currently used.
BACKGROUND
Idiopathic pulmonary arterial hypertension (IPAH)
is a devastating, progressive and still not curable
condition. Complex pathophysiological mechan-
isms, including variable pulmonary vasoconstriction
and remodelling processes of pulmonary arteries,
result in an increased pulmonary vascular resistance
(PVR) with a subsequent reduction of cardiac
output (CO) and, eventually, right heart failure.1
Current approved therapies for the treatment of
PAH have been shown to successfully target the
predominance of vasoconstrictive and proprolifera-
tive mediators, resulting in an increased exercise
capacity and clinical outcome.2 However, treatment
response is not uniform and a more benign as
well as a rapidly progressive course of the disease
may develop. Therefore, parameters that help to
anticipate the natural course of a disease are war-
ranted. This is especially true during first diagnosis
of IPAH.
In this context, acute vasoreactivity testing
during right heart catheterisation (RHC) is recom-
mended to identify a small subgroup of patients
with IPAH with favourable long-term response to
treatment with high dose calcium channel blockers
(CCBs). Acute vasoresponse criteria include a
reduction of mean pulmonary arterial pressure
(PAP) of at least 10 mm Hg to an absolute value
below 40 mm Hg, accompanied by a normalisation
of CO.3 Since this applies to less than 10% of
patients with an otherwise progressive and deadly
disease, it is still important to identify this
phenotype. Pulmonary vasodilators as inhaled
nitric oxide (iNO) or iloprost, or an infusion of
epoprostenol are recommended to quantify the
vasodilative reserve of the pulmonary circulation.4
Consequently, patients with an extensive pulmon-
ary vasodilative response, meeting the strict criteria
of pulmonary vasoresponse, should undergo treat-
ment with solely vasodilating substances, that is,
high dose CCB.4 However, as stated above, this
applies only for a minority of patients with IPAH
and therefore it is implicated that relevant informa-
tion from acute vasodilator testing can only be
drawn for a very small number of patients
with IPAH.
OBJECTIVE
The objective of this study was to evaluate the
prognostic significance of a residual pulmonary
vasodilative reserve during acute testing with
iloprost-aerosol in a cohort of patients with IPAH
not meeting current vasoresponder criteria.
DESIGN AND METHODS
Seventy-two (n=72) consecutive and clinically
stable patients underwent vasoreactivity testing
during RHC mainly during the initial workup of
IPAH.
The diagnosis of IPAH was based on current
recommendations4 after exclusion of significant left
heart and lung disease or other associated condi-
tions. Exclusion of chronic thromboembolic pul-
monary hypertension included a ventilation/
perfusion scan.
Six individuals (n=6) met the current definition
of acute vasoresponse4 during RHC testing and
were excluded from this analysis. RHC
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examinations were mainly done during the process of the first
diagnosis of IPAH (incident cases) and therefore comprised
patients who were therapy naïve for PAH therapies (n=49).
An informed consent was obtained from all patients; the
study was approved by the institutional ethics committee.
Right heart catheterisation and haemodynamic testing
Patients were either naïve for PAH treatments (n=49; 74%) or
PAH treatment was paused 12 h before the RHC.
Our modifications of RHC including a vasodilator test have
been reported before.5 Swan-Ganz Catheterisation (Criti-Cath;
Becton Dickinson; Temse, Belgium) was done over the femoral
vein access. Systemic blood pressure was measured non-
invasively. All measurements were performed in recumbent pos-
ition. Pressures were taken from right atrium and pulmonary
artery (PAP, including pulmonary artery wedge pressure, PAWP).
The mean value of triplicate measures using the thermodilution
method was taken as CO (Cardiac Output Computer; Edwards
Laboratories; Data Ana, USA). In addition, arterial blood gases
and mixed venous oxygen saturation were measured. The PVR,
systemic vascular resistance and cardiac index were calculated
using standard formulas.
After a stable baseline period of at least 20 min (baseline)
each patient inhaled 5 mg of iloprost (Ventavis, BayerVital,
Germany) at mouthpiece over a time period of approximately
15 min.
Haemodynamic variables were taken immediately after stop-
ping the iloprost inhalation and 15 min after the end of the
aerosolisation period and the maximal response was recorded.
Definition of residual pulmonary vasoreactivity
A residual pulmonary vasoresponse was defined as a PVR reduc-
tion (Δ PVR) of ≥30%.6 Additionally, patients were classified
into four categories with regard to the achieved PVR reduction
(ΔPVR ≤−10%, >−10≤−20%, >−20<−30% and ≥−30%).
Survival estimates
The observation period started with the day of the RHC and
ended when the patient died or received lung transplantation
(n=2). These patients were included as ‘alive’ until the day of
transplantation and censored thereafter. All non-survivors died
of cardiorespiratory failure. No patient was lost to follow-up.
Treatment approach
Six patients meeting the definition of positive vasoreactivity
testing were excluded. In the remaining patients, the results of
the vasoreactivity testing did not influence the therapeutic
strategy.
In general, PAH therapy-naive patients were started on either
an endothelin receptor antagonist (ERA) or phosphodiesterase 5
inhibitor (PDE5 I). Since this study was initiated before the
approval of macitentan and riociguat, treatment included bosen-
tan or ambrisentan (ERA) and sildenafil or tadalafil (PDE 5I).
According to Hoeper et al7 and current recommendations2 we
followed a goal oriented escalation of therapies, that is, combin-
ing of two oral drugs before initiating parenteral prostanoid
therapy when individual therapy goals were not met.
Statistical analysis
Values are given as mean, median, SEM and/or minimum/
maximum, respectively. The effect of iloprost-aerosol on haemo-
dynamic parameters and blood gases was calculated in a paired
fashion of the t test. A one factorial analysis of variance
(ANOVA) with Bonferroni correction for multiple testing was
performed when more than two groups were compared. The
prognostic value of each variable was tested by univariate Cox
proportional hazards regression analysis. Survival was derived
from Kaplan-Meier curves. A p value <0.05 was considered




Forty-six female and 20 male patients with IPAH with a mean age
of 52.4±2 years were included. Pulmonary haemodynamics
revealed severe precapillary PH with already reduced CO (table 1).
Haemodynamic effects of iloprost-aerosol
Inhalation of 5 mg of iloprost-aerosol was well tolerated and only
minor side effects (coughing at beginning of the procedure, flush-
ing, slight headache and feeling of warmth) occurred (table 1).
None of these was judged as clinically significant or led to an
early termination of the procedure.
The observed acute haemodynamic response was similar in
pretreated and therapy-naive patients. After the inhalation,
a reduction of mPAP (overall: Δ—11.3%; pretreated Δ—12.7%;
treatment-naive: 10.9%; all p<0.001) paralleled by an increase
of CO (overall: Δ+15%; pretreated: Δ+16%; treatment-naive
Δ+14%; all p<0.001) and mixed venous saturation (overall:
SvO2+6.7 relative%; pretreated: SvO2+7 relative% and
treatment-naive:+6.6 relative%; all p<0.001) was observed.
PAWP was unchanged and the achieved overall PVR reduction
was Δ PVR—24.6% overall, Δ PVR—25.3% in the pretreated
and Δ PVR—24.2% in the treatment-naive patients; (all
p<0.001). While heart rate and oxygenation were not signifi-
cantly affected, a mild reduction of systemic blood pressure was
noted (overall: mean systemic arterial pressure from 92.4±2
mm Hg to 85±2 mm Hg, p<0.001, pretreated: 90±1.7 mm Hg
Table 1 Patient characteristics and haemodynamic response to a single dose of




6 MWD (m) 390±15
Haemodynamic data during vasoreactivity testing
Baseline Iloprost (5μg)
HR (bpm) 77.4±1.8 79.1±2.1
CO (l/min) 4.0±0.13 4.6±0.2***
CI (l/min/m2) 2.2±0.6 2.6±0.9***
RAP (mm Hg) 6.4±0.7 6.8±0.7
PAPmean (mm Hg) 50.6±1.9 44.9±2.0***
PAWPmean (mm Hg) 9.2±0.9 9.5±1
PVR (WU) 11.4±0.6 8.6±0.6***
SAPmean (mm Hg) 92.4±2.0 85.0±2.0***
SaO2 (%) 88.3±1.2 88.1±1.3
SvO2 (%) 56.3±1.3 60.1±1.3***
paO2 (mm Hg) 64.4±2.6 66.0±2.3
paCO2 (mm Hg) 36.3±1.3 35.1±1.4
*p<0.05; **p<0.01; ***p<0.001 compared with baseline.
6MWD, 6 min walking distance; CI, cardiac index; CO, cardiac output; HR, heart rate;
paO2, arterial partial pressure oxygen; paCO2, arterial partial pressure carbon dioxide;
PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR,
pulmonary vascular resistance; RAP, right atrial pressure; SAP, systemic arterial
pressure; SaO2, arterial oxygenation; SvO2, mixed venous oxygenation; WU, Wood
units.
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to 85.5±2 mm Hg p<0.01, treatment-naive 93.4±2.7 mm Hg
to 84.8±2, p<0.001).
In terms of categorised PVR reduction, 10 (2 pretreated
and 8 treatment naive) patients (15%) had Δ PVR of ≤−10%,
17 (3 pretreated and 14 treatment naive) (26%) had a Δ PVR of
>−10≤−20%. In 9 patients (2 pretreated and 7 treatment
naive) (14%) ΔPVR was >−20<−30% and 30 (10 pretreated
and 20 treatment naive) (45%) patients had a ΔPVR of ≥−30%.
Prognostic implication of vasodilator testing
At the end of the observation period (mean observational time
30 months), 50 patients were alive or had undergone lung trans-
plantation, while 16 (n=16; 24.2%) patients had died (table 2).
The observed (transplant free) survival after 1 year, 3 years and
5 years was 91%, 65% and 38%, respectively. Comparing survi-
vors and patients who died during follow-up revealed no signifi-
cant differences with regard to baseline haemodynamics.
However, the haemodynamic response to iloprost-aerosol was
pronounced in the surviving patients. More precisely, the magni-
tude of CO increase and the associated reduction of PVR were
significantly higher in patients who survived despite comparable
baseline haemodynamics.
In addition, the failure to decrease PVR ≥30% was the only
haemodynamic parameter at baseline and during vasoreactivity
testing predictive of mortality (HR 4.6; CI 1 to 20.6, p<0.05)
during univariate analysis. Moreover, patients with preserved
pulmonary vascular reserve (ie, PVR reduction ≥30%) had a
better observed outcome (figure 1). In detail, 2 out of 30 (7%)
patients with a PVR reduction ≥30% died during an estimated
mean survival time of 66.8±4.4 (CI 95% 58.1 to 75.5) months,
while 14 of 36 patients (39%) with less PVR reduction died
during a mean survival time of 47.6±3.7 (CI 95% 38.4 to 56.8)
months (p<0.05).
DISCUSSION
Although significant advances have been made in the diagnosis
and treatment, IPAH remains a devastating and incurable, albeit
treatable condition. However, since treatment response is not
uniform and a more benign as well as a rapidly progressive
course of the disease may develop, parameters that help to
anticipate the natural course of a disease could help to improve
IPAH management. This seems to be especially true for newly
Figure 1 Observed survival (Kaplan-Meier) in pulmonary arterial
hypertension with or without pulmonary vascular resistance (PVR)
reduction ≥30% during vasodilator test with iloprost-aerosol.




Non-survivors (n=16) Survivors (n=50) Non-survivors (n=16) Survivors (n=50)
HR (bpm) 80.0±4.2 76.5±2.0 80.3±4.3 78.8±2.4
ΔHR (bpm) 0.3±1.3 2.2±1.2
CO (L/min) 4.0±0.3 4.0±0.1 4.4±0.3 4.7±0.2
ΔCO (L/min) 0.35±0.1 0.73±0.1*
PAPmean (mm Hg) 47.6±3.2 51.5±2.3 43.6±3.3 45.4±2.3
ΔPAPmean (mm Hg) −4.2±1.4 −6.14±0.85
PAWPmean (mm Hg) 8.8±0.8 9.2±1 8.9±0.7 9.3±1.2
PVR (WU) 10.2±1.0 11.8±0.8 8.6±0.9 8.5±0.7
ΔPVR (WU) 1.6±0.5 −3.2±0.3*
SAPmean (mm Hg) 92.8±4.9 92.3±2.2 83.2±6.1 85.8±4.3
RAP (mm Hg) 7.6±1.4 7.3±0.8 7.8±1 7.2±1.2
SaO2 (%) 87.7±2.2 88.9±1.2 87.7±2.2 88.9±1.2
SvO2 (%) 53.8±2.6 57.3±1.3 57.4±3.3 61.7±1.3
paO2 (mm Hg) 67.4±5.0 64.6±3.1 62.3±4.1 70.5±4
paCO2 (mm Hg) 36.8±1.7 35.9±1.7 34.4±2.3 35.7±1.5
Statistical significances between survivors and non-survivors are given as *p<0.05; **p<0.01; ***p<0.001.
Values are given as absolute and changes (Δ) during vasodilator testing.
6MWD, 6 min walking distance; CO, cardiac output; HR, heart rate; paCO2, arterial partial pressure carbon dioxide; paO2, arterial partial pressure oxygen; PAP, pulmonary arterial
pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SaO2, arterial oxygenation; SAP, systemic arterial pressure; SvO2,
mixed venous oxygenation; WU, Wood units.
974 Leuchte HH, et al. Heart 2015;101:972–976. doi:10.1136/heartjnl-2015-307529
Pulmonary vascular disease
group.bmj.com on May 3, 2017 - Published by http://heart.bmj.com/Downloaded from 
diagnosed (incident) patients.8 Since the care of patients with
IPAH is very complex already, it would be attractive to retrieve
prognostic parameters from already established methods, such
as vasodilator testing during RHC.
This study demonstrates that the acute haemodynamic
response to iloprost-aerosol burrows more information for the
majority of patients with IPAH than currently used to identify a
minority of patients with IPAH who can successfully be treated
with CCB. The key finding of our study is that the extent of a
residual but significant vasodilative reserve, defined as a decrease
of PVR of at least 30% in response to inhalation of 5 mg ilo-
prost, translates into a survival benefit in patients with IPAH.
During acute haemodynamic testing iloprost-aerosol caused
pulmonary vasodilation paralleled by an increase of CO and
SvO2, resulting in a PVR reduction of about 25%. This part of
the study confirms previous data.9 However, this current study
excluded patients meeting current vasoresponder criteria, in
contrast to all previous studies. Therefore acute haemodynamics
were not driven by a small number of patients with a superb
vasoreactivity in this study.
The definition of a positive pulmonary vasodilator test in IPAH
has changed over time. Historically, a significant pulmonary vasor-
eactivity was defined by an acute reduction of the mean PAP and
PVR by at least 20% in response to oral CCB by Rich et al.10 Due
to the occurrence of severe side effects during acute vasodilator
testing with CCB, short acting pulmonary selective vasodilators
such as iNO and intravenous epoprostenol have been introduced
to safely identify patients with a preserved ability to acutely reduce
PVR. Sitbon et al defined a positive vasodilator response as a
decline of the PVR by at least 30% in response to iNO or infusion
of epoprostenol.6 Later, the same authors described the iNO chal-
lenge as a safe method to identify patients with IPAH who would
respond acutely11 and chronically to CCB therapy.3 Meanwhile,
comparable results have been achieved with inhaled iloprost, a
stable prostacyclin analogue predicting clinical response to CCB
treatment.12 Of note, it is not known whether the long-term sur-
vival of classical acute vasoresponders is restricted to CCB treat-
ment, or if any other PAH medication would be equally effective.
However, established PAH drugs (ERA, PDE 5I and Riociguat,
prostanoids and their analogues) have positive effects that may be
attributed to pure pulmonary vasodilation. Therefore these drugs
are also beneficial in so-called patients with non-vasoreactive
PAH.2 One of the explanations for this observation is that these
drugs affect chronic remodelling processes that seem to play a
major role in the development and progression of the disease.
However, IPAH is not a uniform disease and different patho-
physiological aspects may be present to a variable extent in single
patients. Therefore it seems comprehensive to describe an IPAH
phenotype with pulmonary vasodilative reserve, not meeting the
current criteria for CCB treatment.
Since the results of the acute haemodynamic response did not
influence treatment algorithm in this study, it is unclear why this
phenotype translates into survival benefit.
Almost 75% of the study population were patients with newly
diagnosed (incident) IPAH and overall survival was comparable to
previous studies.8 However, only 2 out of 30 patients (7%) with a
PVR reduction ≥30% as compared with 14 out of 36 (39%) died
during follow-up. Considering that pulmonary vasoreactivity and
progressive remodelling are different features (besides others) of
PAH this could lead to either a more benign or a malignant course
of the disease, depending on the extent of each feature.
Current data has led to treatment strategies that favour (early)
combination of available substances, regardless of the initial
haemodynamic status.13 14 Therefore, it is not clear how our
findings could influence these strategies. However, it may offer an
explanation why patients with very comparable characteristics
have different outcomes during treatment. Nevertheless, treatment
strategy should be based on large-scale outcome trials, irrespective
of the residual vasodilative reserve. This is also because patho-
physiologically both groups could benefit from aggressive therapy
strategies, for example, addressing the vasodilative reserve as a
therapeutic target in the respective patient group and combining
PAH drugs in those without vasodilative reserve in terms of a
diminishing progress of the disease.
There are several limitations of this study. First, we could have
missed vasoresponders by not using different substances or higher
doses of iloprost-aerosol during vasoreactivity testing. For
instance, we could have used inhaled NO for pulmonary vasoreac-
tivity testing. However, as compared with iNO, iloprost-aerosol
seems to have pronounced haemodynamic effects in patients with
PAH.14 In addition, the 5 mg iloprost-aerosol approach has been
used in several settings before, especially by Jing et al in order to
identify classical vasoresponders.12 Therefore we are confident of
having chosen a comprehensible approach for the vasodilator test.
Also, since our population is small, and especially in terms of the
observational part of the study, conclusions can only be drawn
with caution. However, IPAH is a rare disease and this size of the
study seems to be comparable to other single-centre trials. Third,
vasoresponse trials especially by Sitbon et al3 have been published
before and have already suggested a better outcome for patients
with pronounced vasoreactivity. However, this study tested differ-
ent substances for vasoreactivity, namely intravenous epoprostenol
and inhaled NO which per se exert very different haemodynamic
profiles as compared with iloprost-aerosol.15 Finally, pretreatment
of PAH with per se vasoactive substances could have influenced
vasoreactivity. However, only a fourth of the patients were pre-
treated and medication was paused 12 h before the RHC. In add-
ition, we did not observe any difference between these groups.
CONCLUSION
These data underline that vasoreactivity testing in IPAH is still
timely and that it holds more information for the majority of
patients than currently used. In addition, we identified residual
pulmonary vasodilative reserve as a prognostic factor in this
devastating disease.
Key messages
What is already known about this subject?
Pronounced vasoreactivity is rare (<10%) in idiopathic
pulmonary arterial hypertension (IPAH). However such (rare)
patients can successfully be treated with high dose calcium
channel blockers. Therefore vasoreactivity testing is required for
every patient with IPAH.
What might this study add?
Vasoreactivity testing also carries prognostic information for the
majority of patients with (IPAH), since the lack of a residual
pulmonary vasodilative reserve seems to be a feature of a
malignant curse of the disease.
How might this impact on clinical practice?
Patients with a missing residual pulmonary vasodilative reserve
have to be identified and very early treatment escalation may be
necessary.
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